EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Leciplex Nanocarriers: An Optimized Platform for Thymol Delivery in Acne Management

Soha Elsalhy iD, Norhan Tantawy, Eman E El Naggar, Wesam E Gawad iD, Amira M Badr iD, Reem T Atawia, Jihad Mahmoud Alsofany iD

Pharmaceutics · 28.06.2026 · 18 (7) · 795

DOI: 10.3390/pharmaceutics18070795 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 28.06.2026. Verfasst von Soha Elsalhy und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, College of Pharmaceutical Sciences and Drug Manufacturing, Misr University for Science and Technology (MUST), Giza 12585…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 109 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: King Saud University, King Saud University, Riyadh, Saudi Arabia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Antibiotics are commonly used for acne treatment. However, increasing bacterial resistance has prompted interest in natural antimicrobial agents, such as thymol (THY), as alternative therapies. This study investigated the effectiveness of Leciplex cationic nanovesicles encapsulating thymol (LPX-THY) as a promising topical acne management strategy.

Methods

Leciplex nanovesicles were assembled using soy phosphatidylcholine (SPC) and cationic surfactants and characterized in terms of particle size, zeta potential, entrapment efficiency, morphology, in vitro release, and ex vivo skin permeation. The optimized formulation was subsequently incorporated into Carbopol/HPMC gel base and evaluated in terms of viscosity, in vitro release, ex vivo skin permeation, in vitro antimicrobial study, and in vivo assessment in a rat model.

Results

Optimal THY-LPX nanovesicles made of SPC and Dimethyldidodecylammonium bromide DDAB in a 1:1 molar ratio showed circular outline with particle size, zeta potential, and entrapment efficiency of 187.7 ± 1.78 nm, 36.97 ±0.21 mV, and 60.5 ± 2.3%, respectively. THY-LPX gel demonstrated minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) at a concentration of 156.25 µg·mL−1 against Staphylococcus aureus, a clear absence of biofilm coating under SEM, and substantial red fluorescence, indicating reduction in viable bacteria under a confocal laser microscope. In vivo study showed enhanced anti-inflammatory effect evidenced by substantial ear skin thickness reduction; 72.7% for THY-LPX gel-treated rats compared to 41.7% and 20% for THY gel and blank LPX gel-treated groups, respectively. Histopathological investigation further confirmed reduced inflammatory response in rats treated with optimized THY-LPX gel.

Conclusions

The developed THY-LPX gel serves as a potential topical delivery platform of THY for acne therapy.

Schlagwörter

Stichwörter der Autor:innen

I-optimal designLeciplexacne vulagrisnano-carrierthymol

Autor:innen und Institutionen

  • Department of Pharmaceutics, College of Pharmaceutical Sciences and Drug Manufacturing, Misr University for Science and Technology (MUST), Giza 12585, Egypt.
  • Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Capital University, Formerly Helwan University, Cairo P.O. Box 11795, Egypt.
  • Department of Pharmaceutical Technology, Faculty of Pharmacy, Horus University, New Damietta 34518, Egypt.
  • Department of Pharmaceutics, Faculty of Pharmacy, Mansoura National University, Gamasa 7731168, Egypt.
  • Department of Microbiology and Immunology, College of Pharmaceutical Sciences and Drug Manufacturing, Misr University for Science and Technology, 6th of October City 12566, Egypt.
  • Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11415, Saudi Arabia.

ORCID-Profile: Soha Elsalhy, Wesam E Gawad, Amira M Badr, Jihad Mahmoud Alsofany

Förderung

  • King Saud University
  • King Saud University, Riyadh, Saudi Arabia

Zitieren

APA

Elsalhy, S., Tantawy, N., El Naggar, E. E., Gawad, W. E., Badr, A. M., Atawia, R. T., & Mahmoud Alsofany, J. (2026). Leciplex Nanocarriers: An Optimized Platform for Thymol Delivery in Acne Management. Pharmaceutics, 18(7), 795. https://doi.org/10.3390/pharmaceutics18070795

Vancouver

Elsalhy S, Tantawy N, El Naggar EE, Gawad WE, Badr AM, Atawia RT, et al. Leciplex Nanocarriers: An Optimized Platform for Thymol Delivery in Acne Management. Pharmaceutics. 2026;18(7):795. doi:10.3390/pharmaceutics18070795

BibTeX
@article{Elsalhy2026,
  author = {Elsalhy, Soha and Tantawy, Norhan and El Naggar, Eman E and Gawad, Wesam E and Badr, Amira M and Atawia, Reem T and Mahmoud Alsofany, Jihad},
  title = {Leciplex Nanocarriers: An Optimized Platform for Thymol Delivery in Acne Management},
  journal = {Pharmaceutics},
  year = {2026},
  volume = {18},
  number = {7},
  pages = {795},
  doi = {10.3390/pharmaceutics18070795}
}
Kostenlos starten →